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Purpose: Stargardt disease 3 (STGD3) is a juvenile macular dystrophy caused by mutations in the elongase of very long-
chain fatty acids-like 4 (ELOVL4) gene, which encodes an elongase involved in the production of extremely long-chain
fatty acids. The STGD3-related mutations cause production of C-terminally truncated proteins (ELOVL4ΔC). STGD3 is
transmitted in an autosomal dominant manner. To date, molecular mechanisms of this pathology have been proposed
based solely on the interaction between wild-type ELOVL4 and ELOVL4ΔC. However, analyses of Elovl4ΔC knockin
mice revealed reduced levels of not only ELOVL4 substrates, but also of fatty acids with a broad spectrum of chain lengths.
Therefore, we investigated the molecular mechanisms responsible for ELOVL4ΔC affecting the entire very long-chain
fatty acid (VLCFA) elongation pathway.
Methods: The ELOVL4ΔC protein was expressed in HEK 293T cells, and its effect on elongase activities toward several
acyl-CoAs were examined. We also investigated the homo- and hetero-oligomerization of ELOVL4ΔC with other
elongases (ELOVL1–7) or with other enzymes involved in VLCFA elongation using coimmunoprecipitation experiments.
Results: We found that ELOVL4ΔC forms a homo-oligomer more strongly than wild-type ELOVL4. ELOVL4ΔC also
interacts strongly with other elongases, although similar interactions for wild-type ELOVL4 were observed as only weak.
In addition, ELOVL4ΔC is able to form an elongase complex by interacting with other components of the VLCFA
elongation machinery, similar to wild-type ELOVL4.
Conclusions: We propose that not only the ELOVL4-ELOVL4ΔC homo-oligomeric interaction, but also several hetero-
oligomeric interactions, may contribute to the pathology of STGD3.
Stargardt disease 3 (STGD3) is a juvenile-onset macular
dystrophy, characterized by gradual loss of central vision,
accumulation of lipofuscin, and window defects in the macula
[1,2]. STGD3, which is transmitted in an autosomal dominant
manner, is caused by mutations in the elongase of very long-
chain fatty acids-like 4 (ELOVL4) gene, which encodes an
elongase involved in the production of extremely long-chain
fatty acids (FAs) [3]. The highest expression of ELOVL4
mRNA has been observed in the retina, followed by the skin,
brain,  and  testis  [3,4].  To  date,  three  types  of  ELOVL4
mutations have been found in STGD3 patients [2]. All of these
mutations  result  in  a  C-terminally  truncated  version
(ELOVL4ΔC) of the protein. In addition, as the wild-type
protein  normally  carries  an  endoplasmic  reticulum  (ER)
retention signal in its C-terminus, all three mutations also
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cause a loss of the ER retention signal. Subsequently, while
wild-type ELOVL4 is localized in the ER, ELOVL4ΔC is
mislocalized to the Golgi or aggresomes [5-7]. Furthermore,
coexpression of ELOVL4ΔC with wild-type ELOVL4 results
in  the  mislocalization  of  the  wild-type  protein  due  to  its
interaction  with  the  mutated  protein  [6-8].  This  effect  is
considered  to  be  the  molecular  basis  for  the  autosomal
dominant transmission of STGD3.
Very long-chain fatty acids (VLCFAs), FAs with a chain
length  of  ≥C20,  function  in  numerous  cellular  processes,
including sphingolipid biogenesis, inflammation, immunity,
fetal  growth  and  development,  retinal  function,  and  brain
development [9-11]. VLCFA elongation occurs in the ER on
acyl-CoAs by adding two carbon units in each cycle, and is
composed  of  four  steps:  condensation,  reduction,
dehydration,  and  reduction  [10].  The  second  and  fourth
reduction steps are catalyzed by the reductases 3-ketoacyl-
CoA  reductase  (KAR)  and  trans-2,3-enoyl-CoA  reductase
(TER),  respectively  [12],  while  3-hydroxyacyl-CoA
dehydratase (HACD) proteins (HACD1–4) are responsible
for  the  third  step,  catalyzing  the  dehydration  of  3-
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2438hydroxyacyl-CoA  [13].  The  first  step  of  the  VLCFA
elongation, condensing malonyl-CoA and acyl-CoA, is rate-
limiting,  and  is  catalyzed  by  one  of  seven  elongases
(ELOVL1–7)  [10,14].  ELOVL1–7  differ  in  substrate
specificities [10,15]. The substrates of ELOVL4 are predicted
to  be  fatty  acyl-CoAs  with  extremely  long  chain-lengths
(≥C26)  [16-18].  Such  FAs  exist  only  in  certain  tissues.
Saturated  FAs  are  observed  in  skin  and  are  used  in  the
formation  of  ceramides,  the  major  lipid  components  of
stratum corneum. Elovl4 knockout mice die soon after birth
due to defects in skin barrier formation [16]. On the other
hand, polyunsaturated, extremely long FAs are found in the
retina, sperm, and brain [2].
In  addition  to  the  Elovl4  knockout  mice,  Elovl4ΔC
knockin mice have been generated and used as a model for
STGD3 [17,18]. The phenotype of homozygous knockin mice
resembles that of the Elovl4 knockout mice: They die within
a few hours after birth, exhibiting severe defects in skin barrier
formation  [17,18].  This  would  suggest  that  the  Elovl4ΔC
protein has no enzyme activity. In addition, heterozygous
Elovl4ΔC knockin mice display STGD3-like phenotypes such
as  progressive  photoreceptor  degeneration  and  the
accumulation of lipofuscin in the retinal pigment epithelium
[19]. Quantitative lipid analyses have demonstrated that the
levels  of  retinal  phosphatidylcholines  with  C32-C36
polyunsaturated  FAs  (PUFAs)  are  reduced  in  the
heterozygous Elovl4ΔC knockin mice [20]. Unexpectedly,
though, not only these ELOVL4 products, but also FAs with
a broad spectrum of acyl-chain lengths, are affected in retinas
by the Elovl4ΔC mutation [19]. This implies that the entire
VLCFA elongation machinery is affected by the Elovl4ΔC
protein.  In  the  present  study,  we  determined  that  the
expression of ELOVL4ΔC does indeed result in the inhibition
of elongase activities toward C16:0-, C18:0-, C18:3(n-6)-, and
C20:4(n-6)-CoAs in vitro. We also found that ELOVL4ΔC
interacts  with  other  ELOVLs,  in  addition  to  its  already
established  homo-oligomeric  interaction  with  wild-type
ELOVL4. Inhibition of the entire VLCFA elongation pathway
due to hetero-oligomer formation may contribute, at least
partly, to the pathology of STGD3.
METHODS
Cell culture and transfection: HEK 293T cells were grown on
0.3% collagen-coated dishes in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma, St. Louis, MO) containing 10%
fetal  bovine  serum  and  supplemented  with  100  units/ml
penicillin and 100 μg/ml streptomycin.
Transfections  were  performed  using  Lipofectamine
PlusTM Reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s  instructions.  Cells  were  grown  to  ~60%
confluency in six-well dishes, and medium was changed to
0.8 ml OPTI-MEM I Reduced-Serum Medium (Invitrogen)
10 min before transfection. Plasmid DNAs (0.5 μg) were
diluted into 100 μl OPTI-MEM I, and 4 μl PLUS reagent was
added to the DNA solution. After a 15 min incubation at room
temperature,  DNA-PLUS  solution  was  mixed  with  3  μl
Lipofectamine reagent diluted with 100 μl OPTI-MEM I, and
the mixture was incubated at room temperature for 15 min.
The DNA-PLUS-Lipofectamine reagent complex was then
added to cells. After incubation at 37 °C for 3 h, the medium
was removed and replaced with normal medium.
Plasmids: The pCE-puro HA-1 and the pCE-puro His6-Myc-1
plasmids  are  mammalian  expression  vectors  designed  to
produce an N-terminal HA-tagged protein and an N-terminal
tandemly oriented His6 and a Myc epitope (His6-Myc)-tagged
protein, respectively. The pCE-puro HA-ELOVLx (where x
is  each  ELOVL  number)  plasmids  have  been  described
previously [13]. The pCE-puro His6-Myc-ELOVL4 plasmid
was constructed by cloning the ELOVL4 gene from the pCE-
puro HA-ELOVL4 plasmid into the pCE-puro His6-Myc-1
vector.
The  KAR  and  TER  genes  were  amplified  from  an
expressed  sequence  tag  (EST)  clone  (ID  3622879;  Open
Biosystems, Huntsville, AL) and from human liver cDNA
(Clontech [TAKARA Bio], Palo Alto, CA), respectively, by
PCR using primers (for KAR, 5′-AGG ATC CAT GGA GAG
CGC TCT CCC CGC CGC CG-3′ [BamHI site underlined]
and 5′-TTT AGT TCT TCT TGG TTT TCT TCA GAT AG-3′;
and for TER, 5′-AGG ATC CAT GAA GCA TTA CGA GGT
GGA GAT TCT G-3′ [BamHI site underlined] and 5′-TTC
AGA  GCA  GGA  AGG  GGA  TGA  TGG  GC-3′).  The
resulting  fragments  were  first  cloned  into  pGEM-T  Easy
vector (Promega, Madison, WI), generating the pGEM-KAR
and pGEM-TER plasmids. The pCE-puro HA-KAR and pCE-
puro  HA-TER  plasmids  were  constructed  by  cloning  the
BamHI-NotI  fragments  of  each  of  the  pGEM-KAR  and
pGEM-TER plasmids into a pCE-puro HA-1 vector.
The  pCE-puro  His6-Myc-ELOVL4ΔC  and  pCE-puro
HA-ELOVL4ΔC plasmids were constructed as follows. The
ELOVL4 gene with a deletion at its 3′-terminus was amplified
by PCR using the primers 5′-AGG ATC CAT GGG GCT CCT
GGA CTC GGA GCC GG-3′ (BamHI site underlined) and 5′-
CAA TCA GCT TCA TAT TTC TCT TTC TTT AAA-3′ from
the pCE-puro HA-ELOVL4 plasmid. The amplified fragment
was  first  cloned  into  the  pGEM-T  Easy  vector,  and  the
BamHI-NotI  fragment  of  the  resulting  plasmid  was
transferred to the pCE-puro HA-1 vector or pCE-puro His6-
Myc-1 vector, producing the pCE-puro HA-ELOVL4ΔC and
pCE-puro His6-Myc-ELOVL4ΔC plasmids, respectively.
In vitro fatty acid elongation assays: In vitro FA elongation
assays  were  performed  essentially  as  described  elsewhere
[21] using total membrane fractions. Cells were suspended in
buffer A (50 mM HEPES-NaOH [pH 6.8], 150 mM NaCl,
10%  glycerol,  1×  protease  inhibitor  mixture  [CompleteTM
EDTA  free;  Roche  Diagnostics,  Indianapolis,  IN],  1  mM
PMSF,  and  1  mM  DTT)  and  lysed  by  sonication.  After
ultracentrifugation (100,000× g, 30 min, 4 °C), the pellet was
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2439suspended in buffer A and was used as the total membrane
fraction. Total membrane fractions (20 μg protein in 19.5 μl
buffer A) were each mixed with 25 μl of 2× assay buffer
(300 mM potassium phosphate buffer [pH 6.8], 10% glycerol,
4 mM MgCl2, 2 mM CaCl2, 2 mM NADPH, 1× protease
inhibitor mixture, 1 mM PMSF, and 1 mM DTT), 2.5 μl of
1  mM  acyl-CoA  (Avanti  Polar  Lipids,  Alabaster,  AL)
complexed with 4 mg/ml FA-free BSA (Sigma), and 3 μl of
25  μCi/ml  [14C]malonyl-CoA  (55  mCi/mmol;  Moravek
Biochemicals, Brea, CA). After a 30 min incubation period at
37 °C, the reactions were terminated by adding 25 μl 75%
KOH (w/v) and 50 μl ethanol, then saponified at 70 °C for 1
h, and acidified by adding 100 μl of 5 N HCl with 50 μl of
ethanol. Lipids were extracted with 750 μl hexane and dried,
then suspended in 30 μl chloroform and separated by normal
phase thin layer chromatography (TLC) on LK5DF Silica Gel
150A TLC plates (Whatman, Kent, UK) with hexane/diethyl
ether/acetic acid (30:70:1, v/v) as the solvent system. Labeled
FAs were detected and quantified by a bioimaging analyzer
BAS-2500 (Fuji Photo Film, Tokyo, Japan).
When  FAs  (eicosapentaenoic  acid  [EPA]  or
docosapentaenoic acid [DPA]) were used in place of acyl-
CoAs, total membrane fractions (20 μg protein in 17.83 μl
buffer A) were each mixed with 25 μl of 2× assay buffer,
0.5 μl of 5 mM FAs (Sigma), 1.67 μl of 0.3 M ATP, 2 μl of
5 mM CoA, and 3 μl of 25 μCi/ml [14C]malonyl-CoA. After
termination of the reactions, lipids were saponified, acidified,
extracted, and separated by TLC, followed by detection and
quantification  by  a  bioimaging  analyzer  BAS-2500,  as
described above.
Statistical  analyses  were  performed  by  a  two-tailed
Student  t  test  using  Microsoft  Excel  software  (Microsoft
Corporation, Redmond, WA).
Immunoblotting:  Immunoblotting  was  performed  as
described previously [22] using the anti-HA antibody HA-7
(1:2,000  dilution;  Sigma),  the  anti-Myc  antibody  PL14
(0.5  μg/ml;  Medical  &  Biologic  Laboratories,  Nagoya,
Japan), or the anti-calnexin (H-10) antibody (0.2 μg/ml; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) as the primary
antibody and horse radish peroxidase (HRP)-conjugated anti-
mouse or anti-rabbit IgG F(ab’)2 fragment (each from GE
Healthcare Bio-Sciences, Piscataway, NJ, and diluted 1:7500)
as  the  secondary  antibody.  Labeling  was  detected  using
ECLTM Reagents or an ECL plus System for Western Blotting
Detection (both from GE Healthcare Bio-Sciences).
Coimmunoprecipitation: HEK 293T cells were transfected
with two plasmids, one carrying HA-tagged genes and the
other harboring Myc-tagged genes. Twenty-four hours after
transfection,  the  cells  were  washed  twice  with  PBS,
suspended  in  buffer  B  (50  mM  HEPES-NaOH  (pH  7.4),
150 mM NaCl, 10% glycerol, 1× protease inhibitor mixture,
1  mM  PMSF,  and  1  mM  DTT),  and  sonicated.  After  a
centrifugation at 300× g for 3 min at 4 °C, the resulting
supernatant was treated with 1% Triton X-100 for 30 min at
4 °C, to solubilize membranes. Samples were centrifuged at
100,000× g for 30 min at 4 °C, and the supernatant was
incubated overnight at 4 °C with the anti-HA antibody HA-7
conjugated to agarose (Sigma). The gel was washed twice
with buffer B containing 0.1% Triton X-100, suspended in 2×
sodium dodecyl sulfate (SDS) sample buffer, and incubated
for 5 min at 37 °C. The obtained precipitates were separated
by SDS–PAGE (PAGE), and subjected to immunoblotting
with the HA7 antibody or an anti-Myc PL14 antibody.
RESULTS
ELOVL4 exhibits no activity toward eicosapentaenoic acid or
docosapentaenoic  acid:  We  recently  performed
comprehensive  in  vitro  analyses  examining  substrate
specificities of all ELOVLs using [14C]malonyl-CoA and 11
acyl-CoAs  (C16:0-,  C18:0-,  C18:1(n-9)-,  C18:2(n-6)-,
C18:3(n-3)-,  C18:3(n-6)-,  C20:0-,  C20:4(n-6)-,  C22:0-,
C24:0-, or C26:0-CoA). In those studies ELOVL4 exhibited
activity toward C24:0- and C26:0-CoAs, but had no activity
toward  the  other  acyl-CoAs  [15].  The  phenotype  of
homozygous Elovl4ΔC knockin mice resembles that of the
Elovl4 knockout mice [17,18], suggesting that the Elovl4ΔC
protein has no enzyme activity. However, to date, the enzyme
activity  of  ELOVL4ΔC  has  not  been  directly  examined.
Therefore, we constructed an ELOVL4ΔC plasmid encoding
an  HA-tagged  mutant  ELOVL4  protein,  which  has  a
truncation  of  the  C-terminal  51  amino  acid  residues,  and
expressed the protein in HEK 293T cells (Figure 1A). We then
performed an in vitro FA elongase assay using total membrane
proteins prepared from HEK 293T cells overproducing HA-
ELOVL4 or HA-ELOVL4ΔC, together with [14C]malonyl-
CoA  and  C24:0-CoA  or  C26:0-CoA.  Consistent  with  our
previous results [15], wild-type ELOVL4 exhibited enzyme
activity toward both C24:0-CoA and C26:0-CoA (Figure 1B).
In  contrast,  ELOVL4ΔC  had  no  activity  toward  either
substrate.
Reportedly, in cell lines that do not express significant
levels  of  ELOVL4  mRNA,  the  expression  of  Elovl4  and
subsequent treatment with the FAs EPA (C20:5(n-3)) or DPA
(C22:5(n-3)) resulted in the production of C28 to C38 PUFAs
[23]. However, reported results were unclear as to whether
these  FAs  were  direct  substrates  of  ELOVL4,  since  no
biochemical  analysis  was  performed.  Therefore,  we
performed an in vitro FA elongase assay using HEK 293T
cells overproducing HA-ELOVL4. Since C22:5(n-3)-CoA is
not commercially available, we used ATP, CoA, and EPA or
DPA, in place of C20:5(n-3)-CoA or C22:5(n-3)-CoA. In this
assay system, EPA or DPA is converted to C20:5(n-3)-CoA
or C22:5(n-3)-CoA, respectively, by endogenous acyl-CoA
synthase using ATP and CoA. For use as controls, HEK 293T
cells were also transfected with vector or with a plasmid
encoding  HA-ELOVL2  or  HA-ELOVL5.  Immunoblotting
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2440demonstrated  that  ELOVL4  was  expressed  at  levels
comparable to those of ELOVL2 and ELOVL5 (Figure 1A).
Consistent with previous reports [21,24,25], ELOVL2, and to
a lesser extent, ELOVL5, exhibited activities toward EPA,
and ELOVL2 was active toward DPA (Figure 1C). However,
ELOVL4 had no activity toward either substrate (Figure 1C).
These  results  suggest  that  neither  C20:5(n-3)-CoA  nor
C22:5(n-3)-CoA is a substrate of ELOVL4.
Figure  1.  ELOVL4  is  not  involved  in  the  elongation  of
eicosapentaenoic acid (EPA) or docosapentaenoic acid (DPA). HEK
293T cells were transfected with a vector (pCE-puro HA-1) or a
plasmid encoding the indicated HA-tagged human ELOVL protein.
A:  Total  membrane  proteins  (3  μg  protein)  prepared  from  the
transfected cells were separated by sodium dodecyl sulfate PAGE
(SDS–PAGE),  and  detected  by  immunoblotting  with  anti-HA
antibodies.  Uniform  protein  loading  was  demonstrated  by
immunoblotting  with  anti-calnexin  antibodies.  B,  C:  Total
membrane proteins (20 μg of protein) were incubated for 30 min at
37 °C with 50 μM acyl-CoA(C24:0-CoA or C26:0-CoA; B) or with
50 μM FAs (EPA or DPA), 10 mM ATP, and 200 μM CoA (C) in
the presence of 1 mM NADPH and 0.075 μCi [14C]malonyl-CoA.
After termination of the reactions, lipids were saponified, acidified,
extracted, and separated by normal phase thin layer chromatography
(TLC), followed by detection and quantification by a bioimaging
analyzer BAS-2500. Values presented represent the mean±standard
deviation (SD) from three independent experiments. Statistically
significant  differences  compared  to  vector-transfected  cells  are
indicated  (**p<0.01;  t-test).  Abbreviations:  IB  represents
immunoblotting, 4 represents ELOVL4; 4Δ represents ELOVL4ΔC;
2 represents ELOVL2; 5 represents ELOVL5.
Expression  of  ELOVL4ΔC  results  in  inhibition  of  other
elongation  pathways  in  which  ELOVL4  is  not  directly
involved:  Lipid  composition  analyses  determined  that  in
retinas of Elovl4ΔC knockin mice, not only levels of C32-C36
lipids, the putative direct products of ELOVL4, but also of
lipids with a broad range of chain-length, are reduced [19,
20].  This  suggests  that  ELOVL4ΔC  inhibits  elongation
reactions that are not catalyzed by ELOVL4. To exclude the
possibility  that  long-term  expression  of  Elovl4ΔC  causes
indirect metabolic or transcriptional changes in lipid-related
genes  in  the  Elovl4ΔC  knockin  mice,  we  introduced
ELOVL4ΔC into HEK 293T cells and analyzed its effects on
endogenous  elongase  activities  toward  C16:0-,  C18:0-,
C18:3(n-6)-,  and  C20:4(n-6)-CoAs.  In  vitro  analyses
previously revealed the responsible ELOVLs active toward
these  acyl-CoAs:  C16:0-CoA,  ELOVL6;  C18:0-CoA,
ELOVL3  and  ELOVL7;  C18:3(n-6)-CoA,  ELOVL5  and
ELOVL7; C20:4(n-6)-CoA, ELOVL2 and ELOVL5 [10,15].
Forty-eight hours after transfection of the cells with vector or
a plasmid encoding wild-type ELOVL4 or ELOVL4ΔC, total
membrane  proteins  were  prepared.  Immunoblotting
demonstrated that wild-type ELOVL4 and ELOVL4ΔC were
expressed at similar levels (Figure 2A). Expression of wild-
type ELOVL4 had no effect on the elongation of C16:0-,
C18:0-,  C18:3(n-6)-,  or  C20:4(n-6)-CoAs  (Figure  2B),
consistent with previous results indicating that these acyl-
CoAs are not substrates for ELOVL4 [15]. On the other hand,
expression of ELOVL4ΔC resulted in a slight but statistically
significant  reduction  in  the  products  of  all  the  tested
elongation reactions (Figure 2B). These results suggest that
ELOVL4ΔC inhibits the entire VLCFA elongation pathway.
ELOVL4ΔC interacts with other ELOVLs: The interaction
between wild-type ELOVL4 and ELOVL4ΔC has already
been established by coimmunoprecipitation, sucrose density
gradient sedimentation, and native PAGE [6-8]. To compare
the  strength  of  interactions  between  ELOVL4-ELOVL4,
ELOVL4-ELOVL4ΔC,  and  ELOVL4ΔC-ELOVL4ΔC,  we
performed coimmunoprecipitation experiments. HA-tagged
ELOVL4 or ELOVL4ΔC was expressed in HEK 293T cells
together with Myc-tagged ELOVL4 or ELOVL4ΔC, and each
was  subjected  to  coimmunoprecipitation  with  anti-HA
antibodies,  following  membrane  solubilization  with  the
nonionic detergent Triton X-100. Myc-tagged ELOVL4 and
Myc-tagged ELOVL4ΔC were each detected as two bands,
which correspond to their glycosylated and unglycosylated
forms  [7]  (Figure  3A).  Expression  of  wild-type  Myc-
ELOVL4 alone did not result in its capture by anti-HA agarose
beads (Figure 3A, lane 8). However, low levels of wild-type
Myc-ELOVL4  were  detected  in  immunoprecipitates  with
wild-type HA-ELOVL4 (Figure 3A, lane 9), suggesting a
weak interaction. Although the Myc-tagged ELOVL4ΔC was
expressed  at  levels  lower  than  those  of  wild-type  Myc-
ELOVL4  (Figure  3A,  lane  4),  higher  levels  of  the  Myc-
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2441ELOVL4ΔC  protein  were  observed  in  the
immunoprecipitates of wild-type HA-ELOVL4 (Figure 3A,
lane 10) than levels of wild-type Myc-ELOVL4 (Figure 3A,
lane 9). These results suggest that the C-terminal deletion
strengthens  the  ELOVL4  homointeraction.  A  similarly
enhanced  interaction  was  observed  between  HA-
ELOVL4ΔC and wild-type Myc-ELOVL4 (Figure 3A, lane
11). Moreover, the interaction between HA-ELOVL4ΔC and
Myc-ELOVL4ΔC  was  even  stronger  than  the  wild-type
ELOVL4-ELOVL4ΔC interaction (Figure 3A, lane 12).
Figure 2. Expression of ELOVL4ΔC reduces endogenous fatty acid
(FA) elongation activities. HEK 293T cells were transfected with a
pCE-puro HA-1 (vector), pCE-puro HA-ELOVL4, or pCE-puro HA-
ELOVL4ΔC  plasmid.  Forty-eight  hours  after  transfection,  total
membrane proteins were prepared from the transfected cells. A: Total
membrane proteins (2 μg of protein) were separated by sodium
dodecyl sulfate PAGE (SDS–PAGE), followed by immunoblotting
with anti-HA antibodies. B: Total membrane proteins (20 μg protein)
were incubated with the indicated acyl-CoA (50 μM) and 0.075 μCi
[14C]malonyl-CoA in the presence of 1 mM NADPH, for 30 min at
37 °C. After termination of the reactions, lipids were saponified,
acidified,  extracted,  and  separated  by  normal  phase  thin  layer
chromatography  (TLC).  The  radioactivities  associated  with  the
reaction product fatty acid (FAs) were quantified using a bioimaging
analyzer BAS-2500. Values shown are relative to those for vector-
transfected cells, and represent the mean±standard deviation (SD)
from  three  independent  experiments.  Statistically  significant
differences  compared  to  vector-transfected  cells  are  indicated
(*p<0.05,  **p<0.01;  t-test).  Abbreviations:  WT  represents  wild-
type; ΔC represents ELOVL4ΔC; vec represents vector.
Since  the  expression  of  ELOVL4ΔC  resulted  in  the
inhibition  of  other  elongation  pathways  not  catalyzed  by
ELOVL4 (Figure 2B), we postulated that ELOVL4 inhibits
other ELOVLs by hetero-oligomer interactions. To test this
possibility,  we  performed  coimmunoprecipitation  analyses
using anti-HA agarose beads, Myc-tagged ELOVL4, Myc-
tagged  ELOVL4ΔC,  and  HA-tagged  ELOVLs.  Although
Figure 3. ELOVL4ΔC interacts with other ELOVLs. HEK 293T cells
were transfected with a pCE-puro HA-1 (vector; A and B), pCE-puro
HA-ELOVL4 (A), pCE-puro HA-ELOVL4ΔC (A), or pCE-puro
HA-ELOVLx plasmid (where x represents each ELOVL number;
B), and with the pCE-puro His6-Myc-1 (vector; A), pCE-puro His6-
Myc-ELOVL4  (A  and  B),  or  pCE-puro  His6-Myc-ELOVL4ΔC
plasmid  (A  and  B).  Total  cell  lysates  were  prepared  from  the
transfected cells and solubilized with 1% Triton X-100. Following
immunoprecipitation with the anti-HA antibody, total lysates (1×)
and bound proteins (A, 8×; B, IB: HA, 1×; B, IB: Myc, 16.5×) were
subjected to immunoblotting with anti-HA or anti-Myc antibodies.
IP, immunoprecipitation; IB, immunoblotting; -, vector; 4, wild-type
ELOVL4; Δ, ELOVL4ΔC; 1, ELOVL1; 2, ELOVL2; 3, ELOVL3;
5, ELOVL5; 6, ELOVL6; 7, ELOVL7.
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2442Myc-tagged wild-type ELOVL4 alone did not bind to anti-HA
agarose (Figure 3B, lane 15), coexpression with one of the
HA-tagged ELOVLs resulted in the recovery of Myc-tagged
wild-type ELOVL4 in the immunoprecipitates, although its
protein levels were low (Figure 3B, odd numbered lanes from
17  to  28).  These  results  suggest  that  wild-type  ELOVL4
interacts with all the ELOVLs, but only weakly. In contrast,
the levels of Myc-ELOVL4ΔC in the immunoprecipitates of
HA-ELOVLs were much higher than those of wild-type Myc-
ELOVL4 (Figure 3B, even numbered lanes from 17 to 28),
similar to interactions previously observed between ELOVL4
and ELOVL4ΔC (Figure 3A), suggesting strong interaction.
These results indicate that ELOVL4ΔC forms not only homo-
oligomers with wild-type ELOVL4 but also hetero-oligomers
with other ELOVLs.
ELOVL4ΔC interacts with KAR and TER: VLCFA elongation
occurs  by  cycling  through  a  four-step  process,  i.e.,
condensation,  reduction,  dehydration,  and  reduction.  We
recently  revealed  that  enzymes  responsible  for  each  step
interact with each other and form an elongase complex [26].
To  examine  whether  ELOVL4ΔC  also  engages  in  the
elongase  complex,  we  conducted  coimmunoprecipitation
analyses of the interactions between ELOVL4ΔC and the
reductases KAR and TER, which catalyze the second and
fourth steps of the VLCFA elongation cycle, respectively
[12]. HA-tagged KAR or TER was expressed in HEK 293T
cells, together with Myc-tagged ELOVL4 or ELOVL4ΔC.
Wild-type Myc-ELOVL4 or Myc-ELOVL4ΔC alone did not
bind to anti-HA agarose beads (Figure 4, lanes 7 and 8).
However,  wild-type  Myc-ELOVL4  was  detected  in
immunoprecipitates with HA-KAR (Figure 4, lane 9) or with
HA-TER  (lane  11),  indicating  that  wild-type  ELOVL4
interacts with KAR and TER. ELOVL4ΔC also interacted
with both KAR and TER, similar to results with the wild-type
protein (Figure 4, lanes 10 and 12). Thus, ELOVL4ΔC can
form the elongase complex.
DISCUSSION
STGD3 is an autosomal dominant macular dystrophy and is
caused by mutations in the ELOVL4 gene [1,2]. ELOVL4 is
an FA elongase whose substrates are considered to be fatty
acyl-CoAs with ≥C26 carbon chain-length, identified using
Elovl4 knockout mice and Elovl4ΔC knockin mice [16-18].
Others had reported that forced expression of Elovl4 in cells
treated with the FA EPA (C20:5(n-3)) or DPA (C22:5(n-3))
produced  PUFAs  with  chain-lengths  of  C28  to  C38  [23].
However, no direct biochemical analyses of ELOVL4 had
been reported. We recently performed in vitro FA elongation
assays using 11 different acyl-CoAs; these studies revealed
that ELOVL4 is active only toward C24:0-CoA and C26:0-
CoA [15]. Here, we likewise found that neither EPA nor DPA
is a substrate of ELOVL4 (Figure 1B). We speculate that
C22:5(n-3)-CoA is first elongated by ELOVL2, then is further
elongated  by  ELOVL4  to  acyl-CoAs  having  ≥26  carbon
chain-lengths.
To date, the autosomal dominant transmission of STGD3
has been thought to be caused only by the interaction between
wild-type ELOVL4 and ELOVL4ΔC. However, in retinas
from Elovl4ΔC knockin mice, the FA composition is broadly
affected  [19],  implying  that  Elovl4ΔC  inhibits  the  entire
VLCFA  elongation  machinery.  In  the  present  study  we
demonstrated that expression of ELOVL4ΔC results in the
inhibition  of  elongation  reactions  toward  C16:0-,  C18:0-,
C18:3(n-6)-,  and  C20:4(n-6)-CoAs  (Figure  2B).  Although
these effects are weak, their long-term influence may cause
multiple types of damage in cellular functions, leading to the
STGD3 pathology. Indeed, development of STGD3 appears
in humans around 14 years of age and in Elovl4ΔC knockin
mice  at  several  months  [19,27].  Although  in  Elovl4ΔC
knockin mice and STGD3 patients, appearance of symptoms
occurs relatively long after birth, in our culture system the
effects of ELOVL4ΔC expression on the elongation of several
FAs were observed within two days. The differences in the
onset of the effect may be due to differences in the expression
levels of ELOVL4ΔC. In Elovl4ΔC knockin mice or STGD3
patients, ELOVL4ΔC must be expressed at levels equivalent
to the allelic wild-type ELOVL4. In our cultured cell systems,
however, ELOVL4ΔC is expressed at much higher levels.
Since  elongation  reactions  toward  C16:0-,  C18:0-,
C18:3(n-6)-,  and  C20:4(n-6)-CoAs  are  catalyzed  by  other
ELOVLs,  we  had  postulated  the  existence  of  hetero-
oligomeric interactions between ELOVL4ΔC and the other
ELOVLs. Although wild-type ELOVL4 interacted with other
ELOVLs only weakly, substantial levels of ELOVL4ΔC did
Figure 4. ELOVL4ΔC engages in the elongase complex. HEK 293T
cells were transfected with a pCE-puro HA-1 (vector), pCE-puro
HA-KAR, or pCE-puro HA-TER plasmid, and with the pCE-puro
His6-Myc-ELOVL4 or pCE-puro His6-Myc-ELOVL4ΔC plasmid.
Total  cell  lysates  were  prepared  from  the  transfected  cells  and
solubilized with 1% Triton X-100. Following immunoprecipitation
with the anti-HA antibody, total lysates (1×) and bound proteins (IB:
HA, 2×; IB: Myc, 5×) were subjected to immunoblotting with anti-
HA  or  anti-Myc  antibodies.  IP,  immunoprecipitation;  IB,
immunoblotting; -, vector; K, KAR; T, TER; 4, wild-type ELOVL4;
Δ, ELOVL4ΔC.
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2443indeed  interact  with  other  ELOVLs  (Figure  3B).  An
enhancement of the homo-oligomeric interaction was also
observed between the C-terminally truncated ELOVL4 and
wild-type ELOVL4 (Figure 3A). To date, 3 mutations have
been found in the ELOVL4 gene in STGD3 patients: a 5 bp
deletion in exon 6 causing the loss of 51 amino acids at the C-
terminus, a 2 bp deletion also leading to loss of the same 51
amino acids, and a nonsense mutation causing a 45 amino acid
truncation [2]. Thus, all mutations cause a loss of at least 45
amino acid residues at the C-terminus; we used the 51 amino
acid  truncation  mutant  for  the  ELOVL4ΔC  in  this  study.
ELOVL4 is a multispan membrane protein and may have
seven  transmembrane  segments,  by  analogy  to  its  yeast
homolog Sur4 [28]. The length of the C-terminal hydrophilic
region (Arg268 to Asp314) is 47 amino acids. Therefore, the
truncation of ELOVL4 observed in STGD3 causes complete
or almost complete loss of the C-terminal hydrophilic region.
Since this C-terminal region is the longest hydrophilic region
in ELOVL4, it may contain residues important for function,
protein–protein  interaction,  and  maintenance  of  proper
structure,  in  addition  to  the  ER  retention  signal  (Lys310-
Ala311-Lys312-Gly313-Asp314)  at  the  C-terminus.
Although only deletion of the C-terminal ER retention signal
has been emphasized in the pathology model of STGD3, we
postulate that other residues in the C-terminal region may also
be involved in this pathology. Loss of such residues may cause
a conformational change in ELOVL4, leading to abnormal
interactions with other ELOVLs.
In yeast, all components of VLCFA elongation form an
elongase complex [28]. Mammalian enzymes also form one
or more elongase complex(es). We previously revealed that
the 3-hydroxyacyl-CoA dehydratase HACD proteins interact
with ELOVLs, with some preferences [13]. HACD1 forms a
complex not only with ELOVLs but also with the reductases
KAR and TER [26]. In the present study, we demonstrated
that  ELOVL4  interacts  with  KAR  and  TER  (Figure  4).
Mammalian FA synthase is a multienzyme that incorporates
all catalytic activities of its cyclic reaction, which is similar to
VLCFA  elongation,  as  discrete  domains  on  a  single
polypeptide  chain  [29].  Like  FA  synthase,  the  adjacent
positioning of the catalytic centers of the four elongation
reactions of VLCFA elongation may contribute to efficient
cycling.
ELOVL4ΔC interacts with other ELOVLs more strongly
than the wild-type protein does, with apparently no specificity
(Figure 3B). ELOVL4ΔC also interacts with KAR and TER,
however  in  this  case  the  strength  of  each  interaction  is
comparable to that observed with the wild-type ELOVL4.
Therefore, it is unlikely that ELOVL4ΔC binds to all proteins
nonspecifically  with  a  similar  affinity.  Nevertheless,  we
cannot exclude the possibility that ELOVL4ΔC also strongly
interacts  with  other  particular  proteins  and  affects  certain
cellular functions. Since ELOVL4ΔC retains an ability to
form the elongase complex, it is possible that ELOVL4ΔC
competes with other ELOVLs when interacting with essential
subunits of the elongase complex such as KAR and TER. In
summary, we propose that several interactions, such as the
already established ELOVL4-ELOVL4ΔC homo-oligomeric
interaction, interactions with other ELOVLs, and interactions
with  other  subunits  of  the  elongase  complex,  contribute
together to the pathology of STGD3.
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